A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Inclusion Criteria:

• Participants must be 18 to 80 years of age, inclusive, at the time of signing theinformed consent.

• Diagnosis of Atopic Dermatitis (AD) as defined by the American Academy ofDermatology (AAD) clinical guidelines (2023) for 1 year or longer at baseline (Day

• Documented history within 6 months prior to Screening Visit, of either inadequateresponse or inadvisability of topical treatments

• Eczema Area and Severity Index (EASI) score of 16 or higher (range, 0 to 72) atbaseline (Day 1)

• Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) scoreof 3 or 4 at baseline visit (Day 1) (on the 0 to 4 vIGA-AD scale, a vIGA-AD score of 3 and 4 represents moderate and severe, respectively).

• AD involvement of 10% or more of Body Surface Are (BSA) at baseline (Day 1)

• Weekly average of daily Peak Pruritis-Numerical Rating (PP-NRS) score of ≥4 atbaseline (Day 1)

• Must have applied a stable dose of topical bland emollient (simple moisturizer, noadditives [eg, urea]) at least once daily for a minimum of 5 out of 7 consecutivedays before baseline (Day 1).

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Skin comorbidity that would adversely affect the ability to undertake AD assessments (eg, psoriasis, tinea corporis, and lupus erythematosus) according to theInvestigator's judgment.

• Known history of, or suspected, significant current immunosuppression

NOTE: The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial